Literature DB >> 15043387

CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections.

Ali M Harandi1, Jan Holmgren.   

Abstract

Recent advances in immunology reveal that vertebrate innate immune systems use pattern-recognition receptors, of which the best characterized is the toll-like receptor (TLR) family, to specifically detect pathogen-associated molecular patterns (PAMPs) present in infectious agents. Based on this, use of synthetic PAMPs has attracted much interest for specific immunoprophylaxis and immunotherapy purposes. Among the PAMPs, immunostimulatory CpG DNA, a TLR9 ligand, displays promising potent immunostimulatory and adjuvanticity in different settings. In this review, recent developments in the use of CpG DNA for inducing immunity in the mucosal tissues will be highlighted.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15043387

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  11 in total

1.  Combining Monophosphoryl Lipid A (MPL), CpG Oligodeoxynucleotide (ODN), and QS-21 Adjuvants Induces Strong and Persistent Functional Antibodies and T Cell Responses against Cell-Traversal Protein for Ookinetes and Sporozoites (CelTOS) of Plasmodium falciparum in BALB/c Mice.

Authors:  Sakineh Pirahmadi; Sedigheh Zakeri; Akram A Mehrizi; Navid D Djadid; Abbas-Ali Raz; Jafar J Sani
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

2.  Vaccine adjuvants CpG (oligodeoxynucleotides ODNs), MPL (3-O-deacylated monophosphoryl lipid A) and naloxone-enhanced Th1 immune response to the Plasmodium vivax recombinant thrombospondin-related adhesive protein (TRAP) in mice.

Authors:  Saeed Nazeri; Sedigheh Zakeri; Akram A Mehrizi; Navid D Djadid; Georges Snounou; Chiara Andolina; François Nosten
Journal:  Med Microbiol Immunol       Date:  2018-06-09       Impact factor: 3.402

3.  Immunological evaluation of two novel engineered Plasmodium vivax circumsporozoite proteins formulated with different human-compatible vaccine adjuvants in C57BL/6 mice.

Authors:  Samaneh H Shabani; Sedigheh Zakeri; Yousef Mortazavi; Akram A Mehrizi
Journal:  Med Microbiol Immunol       Date:  2019-04-25       Impact factor: 3.402

4.  Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.

Authors:  Shailbala Singh; Guojun Yang; Siddappa N Byrareddy; Michael A Barry; K Jagannadha Sastry
Journal:  Vaccine       Date:  2014-11-02       Impact factor: 3.641

5.  Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes.

Authors:  Sara Tengvall; Annika Lundqvist; Roselyn J Eisenberg; Gary H Cohen; Ali M Harandi
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

6.  Identification of immunodominant antigens by probing a whole Chlamydia trachomatis open reading frame proteome microarray using sera from immunized mice.

Authors:  Maria I Cruz-Fisher; Chunmei Cheng; Guifeng Sun; Sukumar Pal; Andy Teng; Douglas M Molina; Matthew A Kayala; Adam Vigil; Pierre Baldi; Philip L Felgner; Xiaowu Liang; Luis M de la Maza
Journal:  Infect Immun       Date:  2010-10-18       Impact factor: 3.441

Review 7.  Oral nanomedicine for modulating immunity, intestinal barrier functions, and gut microbiome.

Authors:  Yonghyun Lee; Nobuhiko Kamada; James J Moon
Journal:  Adv Drug Deliv Rev       Date:  2021-10-26       Impact factor: 15.470

Review 8.  Current state and challenges in developing oral vaccines.

Authors:  Julia E Vela Ramirez; Lindsey A Sharpe; Nicholas A Peppas
Journal:  Adv Drug Deliv Rev       Date:  2017-04-22       Impact factor: 15.470

9.  A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge.

Authors:  Chunmei Cheng; Sukumar Pal; Delia Tifrea; Zhenyu Jia; Luis M de la Maza
Journal:  Microbes Infect       Date:  2013-11-27       Impact factor: 2.700

10.  Induction of protective immunity by vaccination against Chlamydia trachomatis using the major outer membrane protein adjuvanted with CpG oligodeoxynucleotide coupled to the nontoxic B subunit of cholera toxin.

Authors:  Chunmei Cheng; Ilham Bettahi; Maria I Cruz-Fisher; Sukumar Pal; Pooja Jain; Zhenyu Jia; Jan Holmgren; Ali M Harandi; Luis M de la Maza
Journal:  Vaccine       Date:  2009-08-15       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.